IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3626
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$71M
Howard Doong
ABVC BioPharma, Inc. develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer. ABV-1504 has completed Phase II clinical trials for major depressive disorders. ABV1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ABVC ABVC BIOPHARMA, INC. | 39 | 37 | 37 | 49 | - | - | -32.4% | -22.2% | 66.6% | -6419.6% | -6545.5% | 579.5% | 0.0% | 46.0x | $71M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
ABVC BIOPHARMA, INC. (ABVC) receives a "Avoid" rating with a composite score of 39.3/100. It ranks #3626 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
In-line with peers — no strong momentum signal
Fair valuation relative to peers
Average quality profile
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for ABVC.
View All RatingsROIC -99.1% vs WACC 9.7% (spread -108.9%)
GM 67% vs sector 44%, OM -6420% vs sector 3%
Capital turnover 0.85x, R&D intensity 11.4%
Rev growth 579%, 7yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate ABVC BIOPHARMA, INC. (ABVC) as Avoid with a composite score of 39.3/100 at a current price of $1.40. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
ABVC BIOPHARMA, INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 39.3/100 places it at rank #3626 in our full universe.
No Moat
High
Poor
Fair Value
Gross margins of 67% signal strong pricing power.
Stable competitive position in a defensive sector.
Vulnerability to macroeconomic shocks and interest rate volatility.
ABVC BIOPHARMA, INC. represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags ABVC BIOPHARMA, INC. with an Avoid rating, assigning a composite score of 39.3/100 and 1 out of 5 stars. Ranked #3626 of 7,333 stocks, ABVC falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
ABVC's quality score of 37/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -32.4% (sector avg: -1.9%), gross margins of 66.6% (sector avg: 44.1%), net margins of -6545.5% (sector avg: 1.0%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 37/100, ABVC appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 2.53x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
ABVC BIOPHARMA, INC.'s investment score of 18/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 579.5% vs. a sector average of 6.7% and a return on assets of -22.2% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
ABVC is currently showing below-average momentum at 49/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at 579.5% year-over-year, while a beta of 1.03 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
ABVC's stability score of 28/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.03 and a debt-to-equity ratio of 46.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
The short interest score of 57/100 for ABVC suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 46.00x), micro-cap liquidity risk. With a $71M market cap (micro-cap), ABVC BIOPHARMA, INC. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
ABVC BIOPHARMA, INC. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3626 of 7,333 overall (51st percentile). Key comparisons include ROE of -32.4% trailing the -1.9% sector median and operating margins of -6419.6% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While ABVC currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Investment (18) would have the largest impact on the composite score.
ROE 1606% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 51% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 255861% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
SILICON VALLEY, CA - December 2, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. ("ABVC" or the "Company") (NASDAQ: ABVC) today addressed recent public discussions surrounding attention-deficit/hyperactivity disorder (ADHD) treatment in the United States[...
Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance. For the fourth quarter, the company expects revenue of $634 million-$638 million (vs. $636.39 million) and adjusted operating income of $241 million-$247 million. The company's previous implied guidance was $623 million-$648 million in revenue. Wolfe Research analyst Shreyas Patil downgraded Mobileye Global from Outperform to Peer Perform. Mobileye Global shares dipped 23.5% to $30.37 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Minim, Inc. (NASDAQ: MINM) shares jumped 170.2% to $4.62. Omega Therapeutics, Inc. (NASDAQ: OMGA) gained 92.7% to $5.26 after Novo Nordisk entered into a research collaboration with the company. Avenue Therapeutics, Inc. (NASDAQ: ATXI) shares climbed 65.8% to $0.2920 after the company announced it reached a final agreement with the FDA for the Phase 3 safety study for IV tramadol. Jeffs' Brands Ltd(NASDAQ: JFBR) gained 40% to $4.41 after surging 25% on Wednesday. Jeffs' Brands, last month, signed non-binding letters of intent with Sky Growth Partners to invest in a DLP laser-based system for counter-drone solutions and laser-based wireless charging technology. Mobix Labs, Inc. (NASDAQ: MOBX) gained 33.3% to $4.00. Mobix Labs was awarded 15-month contract to supply EMI filtered connectors as part of US Army's M-1 Abrams Tank Program. ATIF Holdings Limited (NASDAQ: ATIF) jumped 30.6% to $1.32. Adicet Bio, Inc. (NASDAQ: ACET) surged 26.1% to $2.22. Adicet Bio issued corporate updates and highlighted upcoming priorities for its pipeline programs in 2024. Smart for Life, Inc. (NASDAQ:
Shares of Resources Connection, Inc. (NASDAQ: RGP) rose sharply in pre-market trading following better-than-expected results for its second quarter. Resources Connection posted quarterly adjusted earnings of 28 cents per share, beating market estimates of 18 cents per share. The company’s quarterly sales came in at $163.1 million versus expectations of $161.936 million. Resources Connection shares jumped 6.5% to $14.58 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Jeffs' Brands Ltd(NASDAQ: JFBR) gained 60.6% to $5.06 in pre-market trading after surging 25% on Wednesday. Jeffs' Brands, last month, signed non-binding letters of intent with Sky Growth Partners to invest in a DLP laser-based system for counter-drone solutions and laser-based wireless charging technology. Kintara Therapeutics, Inc. (NASDAQ: KTRA) rose 41% to $0.1984 in pre-market trading after falling over 11% on Wednesday. Kintara Therapeutics, last month, announced a review of strategic alternatives focused on maximizing stockholder value. The Arena Group Holdings, Inc. (NYSE: AREN) shares rose 26.8% to $2.65 in pre-market trading after falling over 9% on Wednesday. Arena Group Board, last month, terminated employment of CEO Ross Levinsohn. 180 Life Sciences Corp. (NASDAQ: ATNF) shares gained 24.4% to $0.2550 in pre-market ...
Shares of SoFi Technologies, Inc. (NASDAQ: SOFI) fell sharply during Wednesday’s session after Keefe, Bruyette & Woods downgraded rating on the stock. Keefe, Bruyette & Woods analyst Michael Perito downgraded SoFi from a Market Perform rating to an Underperform rating and lowered the price target from $7.50 to $6.50, citing recent outperformance and a change in the analyst's model. SoFi Technologies shares dipped 12.8% to $8.41 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers NexImmune, Inc. (NASDAQ: NEXI) shares rose 150.8% to $6.14 after gaining over 6% on Tuesday. Trinity Place Holdings Inc. (NYSE: TPHS) rose gained 62.6% to $0.1857. The company reported in 8K Filing, mortgage lender agreed to extend the mortgage loan forbearance period to Jan. 31, 2024. Sigma Additive Solutions, Inc.(NASDAQ: SASI) gained 60.3% to $4.65. Sigma Additive Solutions, announced in an 8-K Filing, the approval of the issuance of the shares of common stock in exchange for all the capital stock of NextTrip Holdings. ABVC BioPharma, Inc. (NASDAQ: ABVC) jumped 58.3% to $1.90. ABVC BioPharma and its subsidiary received $460 million from AiBtl BioPharma as the first milestone payment of global licensing fees. Sidus Space, Inc. (NASDAQ: SIDU) rose 48.4% to $10.35. Sidus Space secured NOAA approval to provide imaging services to government and commercial customers. Brera Holdings PLC (NASDAQ: BREA) shares gained 32.8% to $0.97. First Wave BioPharma, Inc. (NASDAQ: FWBI) shares gained 31.2% to $5.01. Roth MKM raised price target on the stock to $40. Elicio Therapeutics, Inc. (NASDAQ: ELTX) gained 29% to $7.65. TDCX Inc. (NYSE: TDCX) gained 28% to $6.18 after it disclosed receiving a preliminary non-binding ...
Shares of American Eagle Outfitters, Inc. (NYSE: AEO) declined during Tuesday’s session after the company reported third-quarter financial results. Net revenue rose 5% Y/Y to $1.30 billion, beating the consensus of $1.28 billion. EPS of $0.49 surpassed the consensus of $0.48. For FY23, AEO revised guidance for revenue to be up mid-single digits Y/Y from growth in low single digits Y/Y earlier. American Eagle fell 16.4% to $16.52 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers Safe and Green Development Corporation (NASDAQ: SGD) shares gained 66% to $4.7119. Safe and Green Development unveiled a Letter of Intent for integration of real estate AI software. Mountain Crest Acquisition Corp. IV (NASDAQ: MCAF) shares jumped 52.4% to $9.92 after falling more than 12% on Monday. Anghami Inc. (NASDAQ: ANGH) shares jumped 36% to $2.1488. OSN Group announced up to $50 million cash investment in Anghami. TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) shares gained 27.9% to $0.2219. TRACON Pharmaceuticals recently announced license of product development platform for $3 million upfront payment. Marpai, Inc. (NASDAQ: MRAI) rose 24.2% to $1.1301. Marpai Form 4 filing showed Eitan Yaron bought 100,000 shares at an average price of $1.23 per share. Symbotic Inc. (NASDAQ: SYM) jumped 23.8% to $46.02 after the company reported better-than-expected fourth-quarter sales results. Burlington Stores, Inc. (NYSE: BURL) gained 19% to $162.77 after the company reported third-quarter financial results and issued guidance. Hibbett, Inc. (NASDAQ: HIBB) jumped 14.7% to $61.55 following strong quarterly sales. LQR House Inc. (NASDAQ: LQR) shares surged 14.5% to $0.0691. LQR House repurchased 1,476,355 shares in its ongoing share ...